MedTrace Logo

Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

NCT01743482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-05-14

No results posted yet for this study

Summary

This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.

Conditions

  • Germ Cell Tumors
  • Measurable Disease

Interventions

DRUG

Pazopanib

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-17
Primary Completion
2016-07-27
Completion
2016-07-27

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01743482 on ClinicalTrials.gov